Glioblastoma multiforme is one of the most aggressive human cancers, and the most common primary, adult CNS neoplasm. Effective treatment strategies are lacking for these tumors, which carry a dismal prognosis. Transgenic mouse models have emerged as powerful tools for studying the biology of glioma [1] . Mice have been engineered to study the effects of manipulating genes and signaling pathways that are known to be mutated or aberrantly regulated in human glioma. We reported a novel transgenic mouse model in which conditional activation of the Ras pathway in the brain led to an intermediate-grade glioma [2] . The glioma showed histopathologic features that closely mimicked human tumors, and glioma cells expressed markers associated with neural stem/progenitor cells (NSPC). In addition, the mice showed marked expansion of the subventricular zone (SVZ), a NSPC population in the brain. This mouse model may be useful for studying the potential role of NSPC in gliomagenesis. More recently, through concomitant, conditional deletion of the p53 tumor suppressor gene, we have developed a novel model of glioblastoma in these mice. This presentation will focus on Cre-loxP technology for introducing genetic manipulations in the brain, and the types of experimental questions that may be addressed.
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Conditional, transgenic mouse models allow targeting of glioma-relevant genetic manipulations to brain cells. One method involves mice that have been engineered to express the DNA recombinase, Cre, under the control of brain tissue-specific promoters (Fig 1) . One such mouse strain, the hGFAP-Cre mouse, expresses Cre protein in restricted brain cell types under the control of the human glial fibrillary acid protein (hGFAP) promoter [3] . These mice are mated with a second genetically engineered mouse strain that carries a mutant form of the proto-oncogene K-ras (Kras G12D ) [4] . This mutant form of K-ras is silenced by stop sequences that are flanked by loxP DNA sequences. Bigenic progeny of this cross (hGFAP-Cre/K-ras G12D mice) inherit both the GFAP-Cre and loxP-stop-loxP-K-ras G12D alleles. Cre expression results in recombination at the loxP sites, excision of the stop sequence, and expression of K-ras G12D . The CNS cell types in which recombination occurs have been well characterized and include NSPC. Additional genetic alterations may be introduced through breeding strategies that incorporate additional conditional alleles.
We have now developed a mouse model of glioblastoma multiforme. p53 mutation is a common genetic alteration in human glioma specimens. Again using hGFAP-Cre mice, we deleted p53 in concert with activation of K-ras G12D . The intermediate-grade gliomas induced by activation of the Kras G12D alone are converted, with concomitant deletion of p53, to high-grade, lethal gliomas (Fig 2) . Microscopic examination of the brains of two-week-old, hGFAP-Cre/K-ras G12D 
/p53
fl/fl pups shows early tumor formation around the SVZ. Cultured astrocytes harvested from hGFAP-Cre/Kras G12D 
fl/fl pups and injected into the brain of adult mice formed lethal tumors at approximately 3 weeks post-injection (Fig 3) . This model may be useful as a pre-clinical tool for studying novel glioma therapies. In addition, it will be possible to use this model to address basic questions about glioma biology, including the role of NSPC, and tumor-microenvironment interactions [5] . 
